According to the Early Treatment Diabetic Retinopathy Study (ETDRS), which of the following defines clinically significant macular edema (CSME)?

## Clinically Significant Macular Edema (CSME) — ETDRS Definition **Key Point:** CSME is defined by specific anatomical criteria that indicate risk of vision loss and warrant treatment. The ETDRS criteria remain the gold standard for identifying eyes at risk. ### ETDRS Criteria for CSME Clinically significant macular edema is present if any of the following is true: 1. **Retinal thickening at or within 500 μm of the foveal center** 2. **Hard exudates at or within 500 μm of the fovea WITH adjacent retinal thickening** 3. **Retinal thickening ≥1 disc diameter in size, any part of which is within 1 disc diameter of the foveal center** ### Why These Criteria Matter | Criterion | Significance | |-----------|-------------| | **500 μm zone** | Represents the critical zone where edema threatens central vision | | **Hard exudates + thickening** | Indicates active capillary leakage and structural damage | | **1 disc diameter zone** | Encompasses the macula region where even mild edema affects acuity | ### Clinical Implications **High-Yield:** CSME is the leading cause of vision loss in nonproliferative diabetic retinopathy. Recognition of CSME criteria is essential for determining treatment urgency. **Treatment Threshold:** - CSME present → Requires laser photocoagulation (focal/grid) or anti-VEGF therapy - CSME absent → Observation with glycemic control and monitoring **Clinical Pearl:** The 500 μm distance is approximately the width of the foveal avascular zone (FAZ), making it a critical anatomical landmark. Optical coherence tomography (OCT) has made CSME detection more precise, but the ETDRS anatomical criteria remain the clinical standard. **Mnemonic:** **CSME = Central + Significant + Macular + Edema** - **C**entral: within 500 μm of fovea - **S**ignificant: hard exudates or thickening - **M**acular: in the macula region - **E**dema: fluid accumulation